Literature DB >> 19657774

Intravenous immunoglobulin therapy for autoimmune diseases.

Yoav Arnson1, Yehuda Shoenfeld, Howard Amital.   

Abstract

Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects caused by the traditional immunosuppressants. One of the noticeable examples of this approach is the increasing use of high-dose intravenous immunoglobulin (IVIg). IVIg mechanisms include modulating function of Fc receptors, interference with complement activation and cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on of T and B cells. In this review we gather existing information regarding IVIg mechanisms of action, clinical applications and its effects on various conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657774     DOI: 10.1080/08916930902785363

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  20 in total

1.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

2.  Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Alexander Krauthammer; Yair Levy; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

Authors:  L Padet; I St-Amour; É Aubin; R Bazin
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 4.  Regaining tolerance to a self-antigen by the modified vaccination technique.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere; Donald Mackay Weir
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

5.  Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.

Authors:  Ekaterina V Medvedeva; Veronika G Dmitrieva; Svetlana A Limborska; Nikolay F Myasoedov; Lyudmila V Dergunova
Journal:  Mol Genet Genomics       Date:  2017-03-02       Impact factor: 3.291

6.  Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.

Authors:  Fabian Käsermann; David J Boerema; Monika Rüegsegger; Andreas Hofmann; Sandra Wymann; Adrian W Zuercher; Sylvia Miescher
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

7.  Limbic encephalitis and related cortical syndromes.

Authors:  Ignacio Rubio-Agusti; Miguel Salavert; Luis Bataller
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

8.  Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells.

Authors:  Nuno Costa; Ana E Pires; Ana M Gabriel; Luiz F Goulart; Clara Pereira; Bárbara Leal; Ana C Queiros; Wahiba Chaara; Maria F Moraes-Fontes; Carlos Vasconcelos; Carlos Ferreira; Jorge Martins; Marina Bastos; Maria J Santos; Maria A Pereira; Berta Martins; Margarida Lima; Cristina João; Adrien Six; Jocelyne Demengeot; Constantin Fesel
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

Review 9.  Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

Authors:  Jeffrey A Bluestone; Hélène Bour-Jordan
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

10.  Epitope predictions indicate the presence of two distinct types of epitope-antibody-reactivities determined by epitope profiling of intravenous immunoglobulins.

Authors:  Mitja Luštrek; Peter Lorenz; Michael Kreutzer; Zilliang Qian; Felix Steinbeck; Di Wu; Nadine Born; Bjoern Ziems; Michael Hecker; Miri Blank; Yehuda Shoenfeld; Zhiwei Cao; Michael O Glocker; Yixue Li; Georg Fuellen; Hans-Jürgen Thiesen
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.